All-trans retinoic acid in solid-tumour immunity: context-dependent signalling, cellular states, and combination therapy
- 1Department of Oncology, The First Affiliated Hospital of Zhengzhou University
Abstract
All-trans retinoic acid (ATRA) influences several processes relevant to cancer immunotherapy, yet its effects in solid tumours range from relief of myeloid suppression to reinforcement of immune tolerance. This divergence reflects the source and duration of retinoid exposure, the molecular state of responding cells and the phase of treatment. We examine these determinants across myeloid, tumour-cell, lymphoid and stromal compartments, distinguishing administered ATRA and ATRA-containing formulations from locally produced retinoic acid (RA) and interventions targeting the RA pathway. Local synthesis and CYP26-mediated catabolism regulate availability, whereas intracellular binding proteins, RAR/RXR complexes, transcriptional coregulators and chromatin influence the response to that exposure. Interactions with interferon, TGF-β, IL-10 and PD-L1 further connect retinoid signalling to immune recognition, regulation and adaptive resistance. Experimental studies support distinct combination strategies based on myeloid differentiation, tumour-cell recognition, preservation of effector function and stromal reprogramming. Human immunotherapy studies show pharmacodynamic activity and combination feasibility, with mixed clinical results across uncontrolled and comparative cohorts. We propose that translation should prioritise a defined, reversible barrier to immunity, pair blood measurements with functional tumour sampling, and compare ATRA-containing treatment with the same partner regimen alone. This approach gives context dependence a testable basis and directs ATRA development towards biologically selected combinations.
Related
- Cellular availability of all-trans-retinoic acid in mice: a pilot study.
- From immunity to identity to exaptation: RNA-based self/non-self discrimination across cellular life
- Glucocorticoid signalling exerts distinct lineage-permissive and dose-dependent disruptive actions during human osteoblast differentiation
- Hierarchical and context-dependent GR-MR signalling governs endogenous corticosteroid decoding in the heart
- NLRP3 signalling in NSCLC: distinguishing expression, inflammasome activation and context-dependent function
BibTeX
@article{han2026alltrans,
title = {{All-trans retinoic acid in solid-tumour immunity: context-dependent signalling, cellular states, and combination therapy}},
author = {Yikai Han and Feng Wang and Taiying Lu},
journal = {Frontiers in Immunology},
year = {2026},
month = oct,
doi = {10.3389/fimmu.2026.1953814},
url = {https://www.frontiersin.org/articles/10.3389/fimmu.2026.1953814/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - All-trans retinoic acid in solid-tumour immunity: context-dependent signalling, cellular states, and combination therapy
AU - Yikai Han
AU - Feng Wang
AU - Taiying Lu
PY - 2026
DA - 2026/10/20
JO - Frontiers in Immunology
DO - 10.3389/fimmu.2026.1953814
UR - https://www.frontiersin.org/articles/10.3389/fimmu.2026.1953814/full
AB - All-trans retinoic acid (ATRA) influences several processes relevant to cancer immunotherapy, yet its effects in solid tumours range from relief of myeloid suppression to reinforcement of immune tolerance. This divergence reflects the source and duration of retinoid exposure, the molecular state of responding cells and the phase of treatment. We examine these determinants across myeloid, tumour-cell, lymphoid and stromal compartments, distinguishing administered ATRA and ATRA-containing formulations from locally produced retinoic acid (RA) and interventions targeting the RA pathway. Local synthesis and CYP26-mediated catabolism regulate availability, whereas intracellular binding proteins, RAR/RXR complexes, transcriptional coregulators and chromatin influence the response to that exposure. Interactions with interferon, TGF-β, IL-10 and PD-L1 further connect retinoid signalling to immune recognition, regulation and adaptive resistance. Experimental studies support distinct combination strategies based on myeloid differentiation, tumour-cell recognition, preservation of effector function and stromal reprogramming. Human immunotherapy studies show pharmacodynamic activity and combination feasibility, with mixed clinical results across uncontrolled and comparative cohorts. We propose that translation should prioritise a defined, reversible barrier to immunity, pair blood measurements with functional tumour sampling, and compare ATRA-containing treatment with the same partner regimen alone. This approach gives context dependence a testable basis and directs ATRA development towards biologically selected combinations.
SN - 1664-3224
ER -